Collegium Pharmaceutical, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone quarterly report; selected fourth-quarter results are included below. Amounts are in U.S. dollars.
Business context
Collegium is a specialty pharmaceutical company focused on pain management. Its marketed products are Xtampza ER, an abuse-deterrent extended-release oxycodone, and Nucynta ER and IR, tapentadol products. The company acquired U.S. commercialization and related assets for Nucynta from Assertio in February 2020 for a stated purchase price of $375.0 million. After the acquisition, Collegium assumed commercialization responsibilities and pays Grunenthal royalties of 14% of Nucynta net sales.
Key financial results
| Metric | 2020 | 2019 |
|---|---|---|
| Net revenue | $310.0 million | $296.7 million |
| Gross profit / gross margin | $179.8 million / 58.0% | $103.0 million / 34.7% |
| Operating expenses | $123.6 million | $126.8 million |
| Operating income (loss) | $56.2 million | $(23.7) million |
| Net income (loss) | $26.8 million | $(22.7) million |
| Operating cash flow | $93.9 million | $27.8 million |
- Revenue increased 4.5%. Xtampza ER generated $128.0 million, up from $105.0 million; Nucynta products generated $182.0 million, down from $191.7 million. Nucynta IR revenue was $116.3 million and Nucynta ER revenue was $65.7 million.
- Gross margin improved substantially, principally as 2019 included $118.6 million in Assertio sales-based royalties, while the acquisition ended those royalty obligations. This benefit was partly offset by higher Nucynta intangible-asset amortization: $60.7 million in 2020 versus $14.8 million in 2019.
- Interest expense rose to $28.9 million from $0.9 million, mainly due to acquisition financing. Income tax expense was $0.8 million; 2019 had no income tax expense.
- Fourth quarter: revenue was $76.3 million versus $74.2 million in Q4 2019; net income was $7.0 million versus a $2.2 million loss. Q4 2020 operating income was $15.0 million.
- Management-reported non-GAAP adjusted EBITDA was $139.7 million versus $8.3 million in 2019; adjusted income was $133.4 million versus $8.6 million. These non-GAAP measures exclude, among other items, amortization, stock compensation and certain interest costs; they are not substitutes for GAAP results.
Cash, liquidity and debt
- At year-end, cash and cash equivalents were $174.1 million; current assets were $277.9 million and current liabilities were $239.5 million. Restricted cash was an additional $2.5 million. Management said cash and expected product cash inflows should fund operations, debt service and capital needs for the foreseeable future under its current plan.
- Cash flow from investing was negative $373.8 million, primarily reflecting the Nucynta acquisition; financing provided $286.5 million. Cash and restricted cash increased $6.6 million during the year.
- Acquisition financing included a $200.0 million secured term loan and $143.75 million face value of 2.625% convertible senior notes due 2026. At year-end, term-loan principal repayments scheduled for 2021–2024 totaled $162.5 million; its balance-sheet carrying value, net of discount and issuance costs, was $157.5 million. Convertible notes had a $99.6 million carrying value, versus $143.75 million principal. The term loan bears interest at three-month LIBOR, subject to a 2.0% floor, plus 7.5%; the convertible notes’ effective interest rate was 10.27%.
- The secured loan requires at least $200 million of annual net sales and restricts certain borrowing, investments and asset dispositions. Collegium reported compliance with all covenants at December 31, 2020. Substantially all material domestic assets secure the loan.
- Contractual obligations totaled $372.7 million, including debt payments and interest, leases and purchase obligations. Working capital was approximately $38.4 million.
Material changes, outlook and risks
- The Nucynta acquisition materially changed the company’s scale, financing and cost profile. It replaced high Assertio royalties with direct Grunenthal royalties, but added substantial debt and amortization expense.
- COVID-19 restricted in-person access to healthcare providers and reduced new patient starts and promotional activity. The company also reported lower travel, marketing and congress-related expenses. Management expected disruption to continue in the near term, with timing uncertain.
- Management provided no specific 2021 revenue or earnings guidance in the supplied filing text. It expects significant commercialization expenses to continue and relies on Xtampza ER and Nucynta sales. Profitability and liquidity depend on sustaining product demand and cash generation.
- Commercial and credit concentration is high: three customers each represented at least 10% of revenue, accounting for 34%, 31% and 31% respectively. They also represented 46%, 34% and 17% of year-end receivables. The company depends on a single supplier for each product’s active pharmaceutical ingredient and relies on contract manufacturers.
- Key exposures include opioid-related litigation and state investigations, Purdue patent litigation involving Xtampza ER and Nucynta, regulatory controls on Schedule II opioids, reimbursement and pricing pressure, and competition. Purdue litigation remained unresolved and the company could not estimate potential losses. Collegium settled Teva’s Xtampza ER patent litigation; under the settlement, Teva may enter the U.S. market on or after September 2, 2033, subject to FDA approval and possible acceleration under specified circumstances.
- The company reported its first annual net income after prior years of losses, but still had an accumulated deficit of $333.1 million. It carried a full valuation allowance against deferred tax assets, and tax attributes may be limited by ownership-change rules.
Important facts for investors to verify
- Underlying sales trends by product, particularly whether Xtampza growth offsets continued Nucynta declines and any remaining COVID-related effects.
- Cash generation after debt service, scheduled term-loan repayments, and the $200 million annual-net-sales covenant.
- Revenue deductions and return reserves: the auditor identified Xtampza ER product-return reserves as a critical audit matter because of estimation uncertainty.
- Customer and supplier concentration, including continuity of active-ingredient supply and manufacturing transitions.
- Developments in Purdue patent and opioid litigation, state investigations, and possible financial or operational consequences.
- The assumptions underlying adjusted EBITDA and adjusted income, and the reconciliation to GAAP results.